Testing a gentler chemotherapy approach for frail adults with acute lymphoblastic leukemia

This trial is testing the EPOCH chemotherapy regimen for adults with acute lymphoblastic leukemia (ALL) who are frail or have significant health conditions that make standard, intensive chemotherapy too risky. The study focuses on patients whose bodies may not tolerate the strongest cancer treatments, offering a more gradual approach that aims to fight the leukemia while keeping side effects manageable. Researchers hope this gentler strategy will work as well as intense treatment but be safer for vulnerable patients.

Standard chemotherapy for ALL can cause severe, life-threatening side effects in older adults or those with other health problems like diabetes or heart disease. This trial exists to find a way to treat ALL effectively in these vulnerable patients without the crushing toxicity that often forces doctors to stop treatment.